ArticleClinical ophthalmology (Auckland, N.Z.)2025
Influence of Retinal Venous Pressure on Visual and Structural Outcomes in Eyes with Central Retinal Vein Occlusion Undergoing Anti-VEGF Treatment.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of intravitreal injection of dexamethasone implant on the corneal morphology of young adults with central retinal vein occlusion.International journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigates the role of retinal venous pressure (RVP) in determining visual and anatomical outcomes in eyes affected by macular edema (ME) secondary to central retinal vein occlusion (CRVO) and treated with anti-vascular endothelial growth factor (VEGF) therapy. Methods: A retrospective observational study analyzed data from 31 eyes of 31 patients with CRVO-induced ME. RVP was quantified using an ophthalmodynamometer, and participants were divided into two cohorts: low RVP (19 eyes) and high RVP (12 eyes). Treatment involved three monthly intravitreal ranibizumab (IVR) injections, followed by a pro re nata (PRN) approach. Visual and anatomical metrics, injection frequencies, RVP levels, and diastolic central retinal artery pressure (CRAP) were monitored over 12 months. Results: At baseline, the low RVP group demonstrated superior mean best-corrected visual acuity (BCVA) in logMAR (P = 0.017), lower central retinal thickness (CRT) (P = 0.018), and higher diastolic CRAP (P = 0.028) compared to the high RVP group. Both groups exhibited significant improvements in BCVA and CRT after 12 months of IVR therapy, with more pronounced gains in the low RVP group for BCVA (P = 0.005) and CRT (P = 0.030). RVP and diastolic CRAP improved in both groups over the study period, with the low RVP group showing greater changes in RVP (P = 0.005) and diastolic CRAP (P = 0.002). Additionally, fewer injections were required in the low RVP group compared to the high RVP group (6.3 vs 7.8, P = 0.017). Conclusion: Eyes with CRVO-associated ME and lower RVP levels exhibit superior baseline visual function, lower CRT, and more favorable outcomes following IVR treatment. Lower RVP is also associated with a reduced injection burden, underscoring its potential as a predictive marker for therapy response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.